Wojtek Wiercioch

TL;DR: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR, addressing the relative merits of using oral H1‐antihistamines, intranasal H1-antihistsamines, IntranasAL corticosteroids, and leukotriene receptor antagonists either alone or in combination.

TL;DR: Recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of an international normalized ratio (INR) range, and a preference for direct oral anticoagulants over VKA for primary treatment of VTE.

TL;DR: These evidence-based guidelines from the American Society of Hematology intend to support patients, clinicians, and others in decisions about preventing VTE in medical inpatients and outpatients with minor injuries and long-distance travelers.

TL;DR: A comprehensive checklist of items linked to relevant resources and tools that guideline developers could consider, without the expectation that every guideline would address each item, is compiled.

TL;DR: The "GRADE-ADOLOPMENT" approach to guideline production combines adoption, adaptation, and, as needed, de novo development of recommendations.